Microbeads are manufactured solid plastic particles of less than one millimetre in their largest dimension. They are most frequently made of polyethylene and are used in exfoliating personal care products, like soaps, facial scrubs and toothpastes or even over-the-counter drugs.
When washed down the drain, microbeads can pass unfiltered through the sewage treatment plants and make their way into rivers and canals, resulting in plastic particle water pollution.
A bench headed by NGT Chairperson Justice Swatanter Kumar asked the government, through the Bureau of Indian Standards, to come out in two weeks with a notification to consider plastic microbeads, which are "5 mm or less, water insoluble, solid plastic particle used to exfoliate or cleanse in a rinse-off personal care products", as unsafe for use.
The direction came after advocate Sumeer Sodhi, appearing for the petitioner, informed the bench that the Ministry of Health has considered the objections of the applicant that no plastic was biodegradable in water.
He told the bench that in May, the ministry had issued a draft notification enlisting all the raw materials that are considered unsafe for use in cosmetics.
The draft notification however only excluded the usage of "non-biodegradable polymeric microbeads," he said.
Later, after NGT's direction to the Health Ministry, the the objections of the applicant were considered and contents of the draft notification finalised, the lawyer said.
The submissions were made during the hearing of a plea filed by Delhi-based lawyer Ashwini Kumar seeking complete ban on the use of microbeads in the manufacture, import and sale of various cosmetics or personal care products.
Kumar has said that microbeads escape the filtration and treatment processes for waste water and end up in rivers, which ultimately lead to the ocean where they contribute to huge chunks of "plastic soup" in the environment.
It had said it was the duty of the government to ensure that no "dangerous" product is allowed to be manufactured or sold to public and had directed the Central Drugs Standard Control Organisation to analyse the products in a laboratory and submit a report in four weeks.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
